SLC29A1 and pancreatic neoplasm: In addition, ASS1-deficient pancreatic cancer cells with ADI-PEG20 and docetaxel resulted in translocation of stabilized c-Myc to the nucleus and subsequent increase of hENT1 cell surface expression, which potentiated the effect of gemcitabine treatment via the increase in gemcitabine uptake and provided valuable evidence of combining ADI-PEG20, gemcitabine, and docetaxel for treating ASS1-negative pancreatic cancer (149).